KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Total Non-Current Liabilities: 2009-2024

Historic Total Non-Current Liabilities for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $20.8 billion.

  • Teva Pharmaceutical Industries' Total Non-Current Liabilities fell 2.16% to $21.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $21.1 billion, marking a year-over-year decrease of 2.16%. This contributed to the annual value of $20.8 billion for FY2024, which is 9.94% down from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Total Non-Current Liabilities stood at $20.8 billion for FY2024, which was down 9.94% from $23.1 billion recorded in FY2023.
  • In the past 5 years, Teva Pharmaceutical Industries' Total Non-Current Liabilities ranged from a high of $26.4 billion in FY2020 and a low of $20.8 billion during FY2024.
  • Its 3-year average for Total Non-Current Liabilities is $22.6 billion, with a median of $23.1 billion in 2023.
  • Data for Teva Pharmaceutical Industries' Total Non-Current Liabilities shows a maximum YoY declined of 9.94% (in 2024) over the last 5 years.
  • Teva Pharmaceutical Industries' Total Non-Current Liabilities (Yearly) stood at $26.4 billion in 2020, then decreased by 3.86% to $25.4 billion in 2021, then dropped by 5.71% to $23.9 billion in 2022, then decreased by 3.50% to $23.1 billion in 2023, then dropped by 9.94% to $20.8 billion in 2024.